Open-label Extension Study Of RN624

• Status: Completed
• Trial end date: 2008-02-11
• Target enrollment: 0
• Participant gender: All

Summary

Study RN624-CL007 is planned to be an open-label protocol to enroll subjects who have previously participated in Study No. RN624-CL006. In this study, subjects will receive RN624 on an open-label basis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Tanezumab

Criteria

Inclusion Criteria:

• Enrolled in Study RN624-CL006

Exclusion Criteria:

• The occurrence of any adverse event or condition during the controlled studies that, in the opinion of the Investigator, should exclude the subject from participating in the open-label extension

• Pregnant or lactating female subjects or subjects who do not agree to use an appropriate form of birth control throughout the study and for 3 months after completing the study